Eli Lilly’s post-earnings decline is creating a buying opportunity for long-term investors


David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Eli Lilly (LLY) reported mixed fourth-quarter results Thursday morning, but we’re looking through the stock’s post-earnings sell-off because there’s no change to the pharmaceutical giant’s bright long-term potential. Notably, the company’s potential blockbuster obesity drug remains on track to be cleared by U.S. regulators by the second half of this year — encouraging news for shareholders, like us at the Club, whose investment case counts on the weight-loss therapy’s success. 



Source link

Leave a Comment